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Heart failure (HF) is a major cause of death in the developed countries (Murray and
Lopez, 1996; Koitabashi and Kass, 2012). Adverse cardiac remodeling that precedes
heart muscle dysfunction is characterized by a myriad of molecular changes affecting
the cardiomyocyte. Among these, alterations in protein kinase pathways play often
an important mediator role since they link upstream pathologic stress signaling with
downstream regulatory programs and thus affect both the structural and functional
integrity of the heart muscle. In the context of cardiac disease, a profound understanding
for the overriding mechanisms that regulate protein kinase activity (protein-protein
interactions, post-translational modifications, or targeting via anchoring proteins) is crucial
for the development of specific and effective pharmacological treatment strategies
targeting the failing myocardium. In this review, we focus on several mechanisms of
upstream regulation of Ca2+-calmodulin-dependent protein kinase II that play a relevant
pathophysiological role in the development and progression of cardiovascular disease;
precise targeting of these mechanisms might therefore represent novel and promising
tools for prevention and treatment of HF.
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Introduction
The human genome consists of approximately 500 different protein kinase genes that ultimately
modify an estimated 30% of the proteome (Hubbard and Cohen, 1993; Graves and Haystead, 2003).
In the heart, protein kinase activity is closely intertwined with different signal transduction cascades
that regulate heart function in both pathologic and physiologic situations (Dhalla andMüller, 2010).
By linking upstream signals with downstream regulatory pathways, protein kinases can affect a broad
range of cellular functions including gene expression, membrane excitability and ion channels, cell
cycle activity, and even metabolism (Bayer and Schulman, 2001; Rybakowska et al., 2015).
One of the well-investigated protein kinases that play a role in adaptive but presumably mainly
in maladaptive remodeling processes in the heart is Ca2+-calmodulin-dependent protein kinase
II (CaM Kinase II or CaMKII). CaMKII is a serine-threonine kinase with a putative dodecameric
structure (Rosenberg et al., 2005) that consists of two hexameric stacked rings as previously described
Abbreviations: b-AR, beta-adrenergic receptor; CaMKII, calcium/calmodulin-dependent protein kinase II; DON,
6-diazo-5-oxo-1-norleucine; EAD, early after depolarization; ECC, excitation–contraction coupling; Epac, exchange
protein activated by cAMP; ETC, excitation–transcription coupling; FFR, force-frequency relationship; GPCR, G-
protein-coupled receptor; HBP, hexosamine biosynthetic pathway; HDAC, histone deacetylase; HF, heart failure; IR,
ischemia-reperfusion; L-NAME, L-NG-Nitroarginine methyl ester; MsrA, methionine sulfoxide reductase A; NOS,
nitric oxide synthase; PDE4D, phosphodiesterase 4D; PKA, protein kinase A—cyclic AMP-dependent protein kinase;
PTM, post-translational modification; RyR, ryanodine receptor; SNO, S-nitrosothiol.
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FIGURE 1 | (A) A schematic representation of a CaMKII monomer,
consisting of a (1) N-terminal catalytic domain, (2) regulatory domain, and
(3) a C-terminal association domain. The most rigorously studied sites for
different post-translational modifications (PTMs) are highlighted in red
below. (B) The association domain (green), which is responsible for
assembly into the holoenzyme, contains a hypervariable domain. Twelve to
fourteen of these subunits multimerize together to form the CaMKII
holoenzyme.
(Hudmon and Schulman, 2002; Anderson et al., 2011). Each
CaMKII monomers consists of three subunits: a catalytic, a
regulatory and an association one (Wang, 2008) that is responsible
for the assembly into the holoenzyme (Rosenberg et al., 2006;
Figure 1).
There are four different products of the CaMKII gene, with
CaMKIId being the most abundantly expressed cardiac isoform
(Hoch et al., 1998; Zhang et al., 2003; Anderson et al., 2011;
Erickson et al., 2013; Gray and Heller Brown, 2014). CaMKII
is critical for cellular processes such as excitation–contraction
coupling (ECC), excitation–transcription coupling (ETC),
chronotropic control via regulation of voltage-gated ion channels
and Ca2+-handling proteins, sarcoplasmatic reticulum (SR)
Ca 2+-uptake and release through ryanodine receptors (RyRs;
Kushnir et al., 2010; Marx and Marks, 2013; Mattiazzi et al., 2015;
Santulli and Marks, 2015).
CaMKII has been further shown to act as a molecular nexus
linking neurohumoral stimulation to adverse cardiac remodeling
and heart failure (HF) upon injury such as pressure overload,
myocardial infarction and/or ischemia-reperfusion (IR; Maier
and Bers, 2002; Zhang et al., 2003; Anderson et al., 2011; Erickson
et al., 2013; Kreusser and Backs, 2014; Kreusser et al., 2014;
Weinreuter et al., 2014; Capel and Terrar, 2015). Autonomous
CaMKII activity seems to be increased in HF, and in patients
with advanced and end-stage HF, there is a significantly up-
regulated expression of CaMKII (Hoch et al., 1998; Maier,
2005). In heart disease, it may be also involved in cell death,
inflammation (Weinreuter et al., 2014), disorders in ECC and
ETC that may ultimately lead to cardiac dysfunction (Mattiazzi
et al., 2015). Hyperactivity of CaMKII can also result in early
after depolarizations (EADs) and proarrhythmic events (Zhang
and Brown, 2004; Couchonnal and Anderson, 2008; Mishra et al.,
2010; Schulman and Anderson, 2010).
As one example for phosphorylation targets, RyRs have been
intensively studied. In the setup of HF, modifications of RyR2 lead
to changes in the intracellular Ca2+ homeostasis that can further
contribute to potentiation and/or perpetuation of maladaptive
stress responses and proarrhythmic events. Whereas S2808 has
been identified as a protein kinase A (PKA) site, CaMKII aims
at S2814 (Ling et al., 2009; Marx and Marks, 2013; Heijman
et al., 2014; Kreusser et al., 2014)—a modification which plays an
important role in the regulation of the force-frequency relationship
(FFR;Kushnir et al., 2010) in the heart.MurinemodelswithRyR2-
S2814Amutation were protected against pressure overload in vivo
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in the setting of transverse aortic constriction (TAC; Respress
et al., 2012). In contrast, mice with a constitutive activation of the
CaMKII site (S2814D) demonstrated exacerbated mortality (van
Oort et al., 2010).
Interestingly, recent studies have argued that specific inhibition
of CaMKII-mediated pathologic signaling might be an effective
therapeutic strategy for addressing HF (Couchonnal and
Anderson, 2008; Sossalla et al., 2010). Likewise, CaMKIIg/d
knockout mice, in which CaMKII activity was completely
abolished in the heart, were protected against cardiac dysfunction
and interstitial fibrosis after pressure overload and b-adrenergic
stimulation (Kreusser et al., 2014; Weinreuter et al., 2014).
Thus, the increasing mechanistic evidence underscores
the need for development of highly specific pharmacological
inhibitors for precise targeting of CaMKII maladaptive functions
without affecting adaptive CaMKII-dependent signaling
pathways, especially in the setting of HF.
Post-Translational Modifications of Protein
Kinases in Heart Disease
Myocardial homeostasis is dictated by the fragile balance between
synthesis and degradation of proteins that control and mediate
folding, trafficking to different compartments of the cell and the
formation of protein complexes. Post-translational modifications
(PTMs) are a highly effective mechanism for regulation of
proteins by changing both structure and function of the affected
targets. For enzymes, such as protein kinases, PTMs might
either stimulate or suppress activity and thus dramatically affect
downstream signaling.
Depending onmechanismof action, PTMs could be subdivided
in three major groups (Liddy et al., 2013):
 Enzymatic: addition or subtraction of the modification
is affected by proteins-such as phosphorylation, O-
and N-linked glycosylation, acetylation, S-nitrosylation,
sumoylation, etc. (Liddy et al., 2013).
 Chemical: e.g., alterations in the pH.
 Physical: e.g., cleavage or degradation of proteins, or
interactions with other proteins, e.g., by building of signaling
complexes.
In the following, we focus on some examples of PTMs that affect
CaMKII function particularly in the heart.
CaMKII and Phosphorylation
Phosphorylation of numerous protein kinases has been argued
to be associated with the pathogenesis and progression of
cardiovascular disease (Palaniyandi et al., 2009; Liu and
Molkentin, 2011; Swaminathan et al., 2012) and has been
shown to affect structure, function, as well as the intracellular
compartmentalization of the target proteins. Extended
Ca2+/CaM association with CaMKII leads to an increased
autophosphorylation of CaMKII (e.g., CaMKIId at the T287
or CaMKIIa at the T286 site; Erickson, 2014). CaMKII
autophosphorylation is important for its activation since it
does not only enhance the affinity of CaM toward CaMKII
(Meyer et al., 1992), but also prevents auto-inhibition of CaMKII
even if Ca2+ decreases, thus conferring residual CaMKII activity
after Ca/CaM dissociation (Lai et al., 1987).
Not only the specific activity of a kinase, but also its
intracellular compartmentalization (cytosolic versus nuclear
localization) depends on a variety of processes, including
alternative splicing, or PTMs. The predominant CaMKII isoform
in the heart—CaMKIId—exists in two splice variants—dB and
dC—that differ in the presence or absence of a nuclear localization
signal (NLS; Zhang and Brown, 2004; Mishra et al., 2011; Gray
and Heller Brown, 2014). As a consequence, the dB isoform more
likely affects gene expression whereas dC is thought to be more
related to regulation of ECC (Zhang and Brown, 2004). However,
neither splice variant is completely exclusive with respect to
its nucleocytoplasmatic distribution as they exist in the same
dodecamers with the consequence that the relative abundance in
the complex may favor nuclear or cytosolic localization (Mishra
et al., 2011). Moreover, as discussed below, phosphorylation of
distinct spice variants may affect subcellular localization (Heist
et al., 1998; Backs et al., 2006). In addition to this, we have shown
that cytosolic CaMKII regulates gene expression by blocking
nuclear import of histone deacetylase 4 (HDAC4; Backs et al.,
2006; Zhang et al., 2007).
Nuclear targeting of CaMKII is regulated by
(auto)phosphorylation (Heist et al., 1998; Bayer and Schulman,
2001; Backs et al., 2006; Rusciano et al., 2012) and might affect
both downstream signaling and transcriptional regulation of
CaMKII (Bayer and Schulman, 2001; Erickson et al., 2008).
CaMKII and Oxidation
Heart failure and many of the conditions that predispose to it
are associated with significant oxidative stress, which could both
be maladaptive and leading to damage to membranes, proteins
and DNA, but also adaptive by conveying specific regulatory
effects (in terms of so-called “redox signaling”), or even activating
physiological signaling pathways (Hafstad et al., 2013). Reactive
oxygen species (ROS) have been reported to lead to a dynamic
PTMatmethionine residues (Erickson et al., 2008). In vitro studies
inwild-type (WT) ormutant variants of Camui—the open formof
CaMKII (Erickson et al., 2011)—reveal that angiotensin II (AngII)
and endothelin-1 (ET1) activateCaMKII by a primarily oxidation-
dependent pathway. Oxidation of M281/282 of CaMKII itself was
shown to activate the kinase, thus underscoring the potential
of oxidative stress to affect both pathologic and physiologic
pathways in excitable cells, such as the cardiomyocyte. Upon
Ca2+/CaM binding at the regulatory CaMKII domain, oxidation
of M281/282 leads to activation of the enzyme (Erickson et al.,
2008). Methionine oxidation inhibits re-association between
regulatory and catalytic subunits of CaMKII (Chao et al., 2010)
and thus enables perpetuation of CaMKII activity. Similarly, it
has been demonstrated that sustained AngII stimulation results in
activation of CaMKII, also increased cardiomyocyte p38 MAPK
activation and apoptosis during transition to HF (Palomeque
et al., 2009). Elevated levels of aldosterone in the circulation could
also lead to an increased CaMKII oxidation, accompanied by
pathological remodeling and cardiac dysfunction (He et al., 2011;
Velez Rueda et al., 2012). In contrast, AngII–induced apoptosis
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was inhibited in isolated cardiomyocytes expressing oxidant-
resistant CaMKII-mutant (Erickson et al., 2008).
Oxidation of CaMKII further affects sodium (Na+) transients
(Wagner et al., 2011) and is thus associated with an increased
susceptibility to arrhythmias due to altered electrical conductivity
(Christensen et al., 2009; Swaminathan et al., 2011). A recent
report showed that oxidative stress and mitochondrial ROS
formation under the conditions of HF could also lead to
oxidation and activation of CaMKIId and dysregulation of Ca2+
homeostasis independent from the Na+- induced Ca2+ overload
(Viatchenko-Karpinski et al., 2014).
Recently, a CaMKII mutant which was resistant to oxidation
modifications (MM281/282VV) was shown also to be protected
upon myocardial infarction when compared to wildtype in the
setup of diabetes (Luo et al., 2013). AMsrA (methionine sulfoxide
reductase) knockout with higher levels of ox-CaMKII was
showing dramatically reduced survival 30 days after myocardial
infarction (Erickson et al., 2008) whereas MsrA overexpression
seemed to be cardioprotective (He et al., 2011; Purohit et al.,
2013). In addition to this, it has also been shown that activation of
the CaMKII is causatively associated with contractile dysfunction
in the setup of ER stress in vivo and that cardio-specific
overexpression of catalase was sufficient to improve and attenuate
ER stress-induced cardiac dysfunction (Roe and Ren, 2013).
CaMKII and Nitrosylation
S-Nitrosylation is a common PTM and consists of S-nitrosothiol
(SNO) formation fromnitric oxide (NO;Choi et al., 2011). During
S-nitrosylation, NO is further processed to dinitrogen trioxide
(N2O3), accompanied by formation of SNO in the protein’s
cysteine thiol residue (Gaston et al., 2003; Choi et al., 2011). ANO-
“equivalent” is then exchanged between two interactingmolecules
(Lander et al., 1997; Stamler et al., 2001; Gaston et al., 2003; Choi
et al., 2011).
S-Nitrosylation might lead to both activation and suppression
of the activity of the affected proteins and so far target proteins
have been identified as ion channels, transmembranous proteins
and different transcriptional factors (Lander et al., 1997; Stamler
et al., 2001; Lima et al., 2010; Choi et al., 2011). Recently, it
has been shown that upon b-AR stimulation, CaMKII can be
activated by increased production of nitric oxide (Gutierrez et al.,
2013). In vitro application of 500 M L-NG-Nitroarginine methyl
ester (L-NAME; an inhibitor of NO synthesis) in cardiomyocytes
reduced Ca2+ sparks during diastole, whereas addition of the
NO donor GSNO increased the rate of Ca2+ sparks and thus
contributed to arrhythmias, possibly via sarcoplasmatic Ca2+
depletion (Gutierrez et al., 2013). C290 has been pointed out
as a predicted CaMKII S-nitrosylation site, although the exact
mechanism bywhich nitrosylation induces CaMKII activity in the
cardiomyocyte is still unclear (Gutierrez et al., 2013).
CaMKII and O-GlcNAcylation
Diabetes mellitus is also a disease where CaMKII activation has
been observed: for example, there is strong evidence indicating
that an increased ox-CaMKII to CaMKII ratio upon myocardial
infarction is associated with higher mortality in diabetic patients
(Luo et al., 2013) in comparison to non-diabetic ones.
Recently, it has been shown that not only oxidation, but also
O-linked glycosylation (O-GlcNAcylation) via activation of the
hexosamine biosynthetic pathway (HBP) might enhance CaMKII
activity. O-GlcNAcylation at S279 might in its turn lead to an
autonomous activation of CaMKII, creating a molecular memory
even after Ca2+-concentration in the cell has declined (Erickson
et al., 2013). High glucose levels induce CaMKII activation as
well as spontaneous SR Ca2+ sparks that can lead to arrhythmias
and contraction impairment in NRVMs (Erickson et al., 2013).
Blocking of O-GlcNAcylation via DON-a pharmacologic HBP
inhibitor—was sufficient to decrease abnormal CaMKII activity
and heart beat irregularities in diabetic animals (Erickson et al.,
2013). Further studies are warranted to learn more about the
relative importance of O-GlcNAcylation versus oxidation of
CaMKII in metabolic disease. It will be also of particular interest
whether distinct modifications lead to activation of CaMKII in
different cellular compartments and could thus modulate the
affinities to certain targets.
Cross-Talk Between Different PTMs
In recent years, there is an overwhelming appreciation for the
diversity of PTMs, but the complex interplay between them is
incompletely understood. In one recent study (Erickson et al.,
2013), O-GlcNAc modification of CaMKII was also linked to
enhanced CaMKII phosphorylation in cardiomyocytes during
periods of elevated glucose levels. Although there is an increasing
evidence for an extensive cross-talk taking place between different
PTMs on example of CaMKII, more elaborated work such as
computational modeling is needed to understand the relative
contribution of these interactions in the context of cardiac health
and disease.
Table 1 indicates the most often encountered PTM-sites within
the regulatory unit of CaMKII and highlights the regulatory
pathways and disease states that affect those modifications.
Interaction of Other Pathways With CaMKII
Signaling
The close interaction between PKA and CaMKII is known
for a long time (Haghighi et al., 2014). Recently, it has been
reported that CaMKII affects cAMP levels both under normal
conditions and upon b-adrenergic stimulation (Mika et al., 2015)
via regulation of PDE4D (phosphodiesterase 4D).
Another example for the extensive cross-talk between PKA
and CaMKII pathways has recently revealed that both signaling
pathways are not mutually exclusive, but often complementary
to each other (Pereira et al., 2013). In this paper, the authors
claim that Epac (exchange protein activated by cAMP) activation
upon b-adrenergic stress can lead to arrhythmogenic SR Ca2+
release that involves increased phosphorylation of the RyR by
CaMKII (Pereira et al., 2013). In particular, the Epac2 isoform
was specifically shown to mediate Ca2+ release from the SR in
a PKA-independent fashion by S2814 phosphorylation (Pereira
et al., 2013).
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TABLE 1 | The most important PTMs affecting CaMKII function in the heart in terms of the modification sites, the conditions, under which PTMs are
observed and their effect in the heart.
Modification Site Disease/stimuli Effect Citation(s)
Phosphorylation T286/287 Atrial fibrillation, sympathetic stimulation Perpetuated activation Lai et al. (1987), Heist et al. (1998),
S332 Blocked nuclear signaling Bayer and Schulman (2001)
Oxidation M280/281 ROS, diabetes, Activation angiotensin II injury Palomeque et al. (2009), Swaminathan et al. (2011),
Luo et al. (2013), Purohit et al. (2013)
O-GlcNAcylation S279/280 Diabetes Activation Erickson et al. (2013)
S-Nitrosylation C290 b-Adrenergic receptor (b-AR) stimulation Activation, ryanodine receptor Choi et al. (2011)
phosphorylation
The extensive interactions between PKA andCaMKII signaling
pathways with far-reaching consequences on the cardiac genome
could also be demonstrated on their effects on different members
of the HDAC family, such as HDAC5. Acute b-adrenergic
stimulation and/or PKA activation has been shown to enable
nuclear retention of HDAC5 (Ha et al., 2010; Sucharov et al.,
2011; Haworth et al., 2012; Chang et al., 2013). During acute
adrenergic stress, PKA activation could at least party dominate
over CaMKII/PKD signaling pathways to provide a short time
frame for protection against damage. However, there is still
a controversy as to whether PKA leads to HDAC5 nuclear
retention by direct phosphorylation of HDAC5 (Ha et al.,
2010; Chang et al., 2013) or whether PKA leads to HDAC5
nuclear retention via phosphorylation-independent (Haworth
et al., 2012) or indirect (Sucharov et al., 2011) mechanisms, e.g.,
via inhibition of PKD. Future work is needed to clarify these
different findings/hypotheses.
Moreover, our recent data unmasked a PKA-dependent
signaling pathway by which PKA overcomes CaMKII-
dependent epigenetic signaling toward HDAC4 (Backs et al.,
2011). PKA induces proteolysis of HDAC4, generating a
stably expressed N-terminal HDAC4 fragment (HDAC4-
NT) that could in turn selectively enter the nucleus and
suppress gene programs which drive pathological remodeling
(such as the transcriptional factor MEF2), without affecting
cardiomyocyte survival. Remarkably, HDAC4-NT is resistant
to CaMKII because it lacks the CaMKII phosphorylation sites:
a finding which might facilitate the development of NT-based
therapeutic approaches for circumventing pathological CaMKII
signaling.
On the other hand, activated CaMKII stably associates
with full-length HDAC4, but not directly with HDAC5, which
responds only to CaMKII when associated with HDAC4 (Backs
et al., 2006, 2008). This implies that the interaction between
CaMKII and HDAC4 is critical for downstream transcriptional
regulation in response to Ca2+ signaling; for example, a CaMKII-
non-responsive HDAC4 mutant was resistant to prohypertrophic
signaling (Backs et al., 2006). Further screening for identifying
pharmacological inhibitors that interrupt specifically this
CaMKII/HDAC4 interaction is underway Backs et al.
(unpublished).
Another group of proteins that closely interact with CaMKII
are beta-arrestins (Reiter et al., 2012). Upon binding to G-protein-
coupled receptors (GPCRs), they function as adaptor molecules
that can scaffold numerous proteins involved in cardiovascular
diseases, e.g., cAMP phosphodiesterase, PDE4D, kinases such as
ERK1/2, and CaMKIId (Perry et al., 2002; Wu et al., 2006; Xiao
et al., 2007; Gurevich et al., 2008). In vivo models of HF suggest
a beneficial function of b-arrestin-mediated ERK stimulation
via both b-1-adrenergic and AngII Type 1A receptors (Tohgo
et al., 2003; Zhai et al., 2005; Noma et al., 2007; Gurevich et al.,
2008; Chiara Andreoli, 2013). In contrast, b-arrestin-mediated
activation of CaMKIId can triggermaladaptive events (Mangmool
et al., 2010; Bathgate-Siryk et al., 2014). Due to the selective effects
of b-arrestin on cardiac homeostasis, future therapeutic efforts
might focus on development of the so-called “biased ligands” that
could counteract maladaptive and stimulate adaptive G-protein
signaling (Patel et al., 2008).
Furthermore, recent observations on the role of CaMKII in
left ventricular hypertrophy in the setup of hypertension have
provided some interesting evidence regarding the reciprocal
activation of CaMKII and ERK (extracellular regulated kinase;
Cipolletta et al., 2015). In this particular study, in vivo treatment
with inhibitors of CaMKII lead to an inhibition of cardiomyocyte
hypertrophy-a finding which went along with a reduction of
CaMKII and ERK phosphorylation and nuclear accumulation
(Cipolletta et al., 2015).
miRNAs
It has been also recently reported that CaMKII could be
regulated via different microRNAs, such as miR-145 and that
miR-145 affects CaMKIId-regulated transcriptional programs
(Cha et al., 2013). Another member of the micro RNA family:
miR-214 has been shown to be cardioprotective in the setup
of IR injury by counteracting Ca2+ overload in response
to impairment of coronary blood flow through inhibition of
CaMKIId—the main CaMKII isoform in the heart (Aurora et al.,
2012).
Other Modifications
Whereas the role of furthermodifications—such as ubiquitination
of CaMKII have been implicated to mediate in the synaptic
plasticity in neurons (Tsai, 2014), similar modifications and the
role of the proteasome in the regulation of CaMKII activity in the
heart still remain to be further elucidated.
Proteolysis
Calpains catalyze the proteolysis of numerous and diverse
cytosolic, cytoskeletal, and membrane-associated substrates in
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response to cell injury in vivo and in vitro (Tremper-Wells and
Vallano, 2005). In primary neuronal cultures, calpain-mediated
proteolysis of nuclear CaMKIV under conditions of sustained
Ca2+ activity affects CaMK-dependent gene transcription,
thereby preventing excessive transcriptional response (Tremper-
Wells and Vallano, 2005). Proteolysis has not been directly
investigated as a possible mediator of CaMKII activity in the
heart yet; however, the increasing evidence from investigations
in the neurovascular field suggests that there are still plenty
of unexplored mechanisms of CaMKII regulation that extend
beyond our current scope of knowledge. Although CaMKIV has
been long thought to be a kinase with expression pattern limited
only to neuronal tissue, recently it was shown that this particular
CaMK—variant contributes to controlling nitric oxide synthase
(NOS) activity in endothelial cells (Santulli et al., 2012)—a finding
that uncovered a previously unknown mechanism for CaMK-
dependent blood pressure control. A genome-wide analysis
done several years ago within the Framingham Heart Study
100K Project (Larson et al., 2007; Santulli et al., 2012) has
pointed out an important links between vessel wall stiffness
and variants of the human CaMKIV gene and thus opened
room for discussions regarding the role of other CaMK
family members in the regulation of cardiovascular health and
disease.
Summary
The mammalian heart responds to perpetuated stress with a
remodeling process that is characterized by myocyte hypertrophy,
alterations in ion currents and impaired contractility that
ultimately culminate in HF. Among the plethora of molecular
changes that occur during pathological cardiac remodeling
alterations in the expression, structure, enzymatic activity and/or
sub-cellular localization of a number of protein kinases are often
critically involved in maladaptive signaling.
As a member of the protein kinase family, CaMKII represents
an important nodularmolecule translating different types of stress
into both pathological and physiological downstream pathways in
the heart and has therefore emerged as a promising therapeutic
target in the context of HF. A profound understanding of
CaMKII’s regulatory mechanisms under different stress situations
might enable the future development of pathway-or disease-
specific CaMKII-based therapies that combine high treatment
efficacy with low potential for off-target effects.
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